3-(哌啶-4-基)苯并[d]异恶唑 | 84163-68-8

• 物质功能分类: 有机原料 - 酮类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并异恶唑
• 中文名称: 3-(哌啶-4-基)苯并[d]异恶唑
• 中文别名: 3-哌啶-4-苯并[d]异噁唑
• 英文名称: 3-(piperidin-4-yl)benzo[d]isoxazole
• 英文别名: 3-(4-piperidyl)-1,2-benzisoxazole；3-piperidin-4-yl-1,2-benzoxazole
• CAS: 84163-68-8
• 化学式: C₁₂H₁₄N₂O
• mdl: MFCD08166653
• 分子量: 202.256
• InChiKey: KEIQPPQTKPFHLZ-UHFFFAOYSA-N

物化性质

• 沸点：
  355.5±35.0 °C(Predicted)
• 密度：
  1.143±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  38.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  3-(哌啶-4-基)苯并[d]异恶唑 在 potassium carbonate 、 过氧化苯甲酰 作用下， 以 苯 为溶剂， 以7.5 g (97%)的产率得到3-(1-benzoyloxy-4-piperidyl)-1,2-benzisoxazole
  参考文献：
  名称：

  3-(4-Piperidyl)-1,2-benzisoxales

  摘要：

  公开了新颖的3-(4-哌啶基)-1,2-苯并异噁唑、其中间体及其制备方法，以及利用这些化合物或其组合物缓解疼痛的方法。

  公开号：

  US04355037A1
• 作为产物：
  描述：

  2-氟苯腈 在 氢氧化钾 、 盐酸羟胺 作用下， 以 乙二醇乙醚 、 乙醇 、 甲苯 为溶剂， 反应 37.0h， 生成 3-(哌啶-4-基)苯并[d]异恶唑
  参考文献：
  名称：

  Synthesis and neuroleptic activity of 3-(1-substituted-4-piperidinyl)-1,2-benzisoxazoles

  摘要：

  The synthesis of a series of 3-(1-substituted-4-piperidinyl)-1,2-benzisoxazoles is described. The neuroleptic activity of the series was evaluated by utilizing the climbing mice assay and inhibition of [3H]spiroperidol binding. Structure-activity relationships were studied by variation of the substituent on the benzisoxazole ring with concomitant variation of four different 1-piperidinyl substituents. Maximum neuroleptic activity was realized when there was a 6-fluoro substituent on the benzisoxazole ring. The 1-piperidinyl substituent appeared less significant, although in most cases, the (1,3-dihydro-2-oxo-2H-benzimidazol-1-yl)propyl group imparted maximum potency. The most potent compound in both assays was 6-fluoro-3-[1-[3-(1,3-dihydro-2-oxo-2H-benzimidazol-1-yl) propyl]-4-piperidinyl]-1,2-benzisoxazole (11b).

  DOI：

  10.1021/jm00383a012

文献信息

• 1,2-benzisoxazole compounds
  申请人：Adir et Compagnie

  公开号：US05100902A1

  公开（公告）日：1992-03-31

  Compounds of formula I ##STR1## in which m represents an integer from 0 to 5, n represents an integer from 1 to 2, p is equal to 0, 1 or 2, X, Y and Z, which may be identical or different, each represent a hydrogen atom, a halogen atom, a linear or branched alkyl radical, a trifluoromethyl radical, an alkoxy radical, an alkylthio radical or a hydroxyl radical, and R represents a 2-benzofuranyl or 2,3-dihydro-2-benzofuranyl radical (it being possible for each to be substituted on the benzene ring), a 2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran-2-yl radical, a 4-oxo-4H-chromen-2-yl radical (optionally substituted on the benzene ring), a benzocyclobutenyl radical of formula A or an indanyl radical of formula B: ##STR2## (in which: R.sub.1 and R.sub.2, which may be identical or different, each represent a hydrogen atom, a halogen atom, a trifluoromethyl radical, an alkyl radical, an alkoxy radical, a hydroxyl radical, a hydroxyalkyl radical or an alkylthio radical, or together form a methylenedioxy radical or an ethylenedioxy radical, and R.sub.3 represents a hydrogen atom or a linear or branched alkyl radical having 1 to 6 carbon atoms), or a radical of formula C: ##STR3## (in which R.sub.4, R.sub.5 and R.sub.6, which may be identical or different, each represent a hydrogen atom, a halogen atom, a trifluoromethyl radical, a hydroxyl radical, an alkyl radical, an alkoxy radical or an alkylthio radical, their optical isomers and their addition salts with a pharmaceutically acceptable organic or inorganic acid.

  式I的化合物##STR1##中，其中m表示0到5的整数，n表示1到2的整数，p等于0、1或2，X、Y和Z，可以相同也可以不同，每个代表氢原子、卤素原子、直链或支链烷基基团、三氟甲基基团、烷氧基团、烷基硫基团或羟基基团，而R代表2-苯并呋喃基或2,3-二氢-2-苯并呋喃基（每个都可以在苯环上被取代），2,3,6,7-四氢苯并[1,2-b:4,5-b']二呋喃-2-基基团，4-氧代-4H-香豆素-2-基基团（在苯环上可选择取代），A式苯并环丁烯基基团或B式茚基基团：##STR2##（其中：R.sub.1和R.sub.2，可以相同也可以不同，每个代表氢原子、卤素原子、三氟甲基基团、烷基基团、烷氧基团、羟基基团、羟基烷基基团或烷基硫基团，或者一起形成亚甲二氧基基团或乙烯二氧基基团，而R.sub.3代表氢原子或具有1到6个碳原子的直链或支链烷基基团），或C式基团：##STR3##（其中R.sub.4、R.sub.5和R.sub.6，可以相同也可以不同，每个代表氢原子、卤素原子、三氟甲基基团、羟基基团、烷基基团、烷氧基团或烷基硫基团，它们的光学异构体及其与药学上可接受的有机或无机酸的加合盐。
• Solution-Phase Synthesis of a Diverse Library of Benzisoxazoles Utilizing the [3 + 2] Cycloaddition of in Situ-Generated Nitrile Oxides and Arynes
  作者：Anton V. Dubrovskiy、Prashi Jain、Feng Shi、Gerald H. Lushington、Conrad Santini、Patrick Porubsky、Richard C. Larock

  DOI：10.1021/co300159g

  日期：2013.4.8

  the [3 + 2] cycloaddition of nitrile oxides with arynes and further diversified by acylation/sulfonylation and palladium-catalyzed coupling processes. The eight key intermediate benzisoxazoles have been prepared by the reaction of o-(trimethylsilyl)aryl triflates and chlorooximes in the presence of CsF in good to excellent yields under mild reaction conditions. These building blocks have been used

  苯并异恶唑的文库是通过腈与芳烃的[3 + 2]环加成反应合成的，并通过酰化/磺酰化和钯催化的偶联过程进一步多样化。八种关键中间体苯并异恶唑是通过在CsF存在下，邻-（三甲基甲硅烷基）芳基三氟甲磺酸酯和氯肟在温和的反应条件下以良好或优异的收率反应制得的。这些构件已被用作各种3,5,6-三取代的苯并异恶唑的关键组分。
• CONDENSED LACTAM DERIVATIVE
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：US20200172543A1

  公开（公告）日：2020-06-04

  The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.

  本发明涉及一种用于治疗神经精神疾病的药物，包括以下化合物（1）的药物学上可接受的盐，作为活性成分。
• SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES
  申请人：Pouzet Pascale

  公开号：US20110021501A1

  公开（公告）日：2011-01-27

  The invention relates to new piperidino-dihydrothienopyrimidines of formula 1, as well as pharmacologically acceptable salts thereof, wherein X is SO or SO 2 , but preferably SO, and wherein R 1 , R 2 , R 3 and R 4 may have the meanings given in claim 1 , as well as pharmaceutical compositions which contain these compounds. These new piperidino-dihydrothienopyrimidines are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers.

  本发明涉及通式1的新哌啶二氢噻吩并嘧啶类化合物及其药理上可接受的盐，其中X为SO或SO2，优选SO，并且其中R1、R2、R3和R4可具有权利要求1中所述的含义，以及含有这些化合物的药物组合物。这些新哌啶二氢噻吩并嘧啶类化合物适用于治疗呼吸系统或胃肠道疾病、关节、皮肤或眼睛的炎症性疾病、周围或中枢神经系统疾病或癌症。
• PROCESS FOR THE PREPARATION OF PALIPERIDONE AND ITS INTERMEDIATES
  申请人：Thangavel Arulmoli

  公开号：US20100298566A1

  公开（公告）日：2010-11-25

  A process for the preparation of a psychotropic agent Paliperidone. Preferably, this invention relates to a method for the purification of Paliperidone by making its acid addition salts.

  一种制备精神药物帕利哌酮的方法。优选地，本发明涉及通过制备其酸盐来纯化帕利哌酮的方法。